A Single Center Experience in the Management Adverse Event in Heavily Pretreated Melanoma Patients in an Ipilimumab Expanded Access Programme at the Klaipeda University Hospital
Alvydas Česas, Asta Poškienė, Jolanta Česienė Abstract The incidence of metastatic melanoma has increased over the past three decades, and the death rate continues to rise faster than the rate with most cancers [1]. The survival rate for patients with metastatic melanoma is low, with an expected 2-year survival rate of 10 to 20%. Ipilimumab-immunotherapeutic,…